POMDOCTOR LIMITED, a digital healthcare company listed on NASDAQ, outlined a four-tier diversified revenue structure designed to build on its established internet hospital, physician network and pharmaceutical supply chain while scaling technology-enabled services. The four tiers are B2C basic healthcare services, AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, and pharmaceutical real-world study (RWS) and real-world data (RWD) services.
The company reported audited net revenues of RMB399.9 million (approximately US$59.04 million) for fiscal 2025, compared with RMB304.9 million in 2023 and RMB342.6 million in 2024, and believes this growth provides a foundation for additional AI-driven, recurring and institutional revenue streams. Management emphasized that traditional healthcare operations remain central, while AI, wearable technologies, remote patient monitoring and data capabilities are being integrated to build a predictive healthcare data and services infrastructure.
POMDOCTOR LIMITED, a digital healthcare company listed on NASDAQ, describes its strategy to build a healthcare data ecosystem to support AI-powered chronic disease management and predictive healthcare services. The company aggregates real-world data from wearable devices, remote patient monitoring, physician interactions, patient health management and healthcare payment-related activities.
Management emphasizes that high-quality real-world data is a core asset for AI platforms and expects continuous data flows to improve AI models and risk analysis. Industry research cited in the report projects strong global growth in real-world data markets, driven by electronic health records, telehealth, wearable devices and demand for personalized medicine.
POMDOCTOR LIMITED, a digital healthcare company listed on Nasdaq under the symbol POM, reports that it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). Nasdaq notified the company on July 10, 2026 that the matter is closed after its American Depositary Shares (ADSs) maintained a closing bid price at or above $1.00 for 10 consecutive business days from June 25 to July 9, 2026.
The company had previously received a Nasdaq notice on January 29, 2026 after its ADS closing bid price stayed below $1.00 for 30 consecutive business days. With compliance restored, POMDOCTOR’s ADSs will continue to be listed on Nasdaq, and the company continues to focus on AI-enabled and predictive healthcare solutions.
POMDOCTOR LIMITED outlined its strategy to build an AI-enabled chronic disease management ecosystem, integrating artificial intelligence, remote patient monitoring, wearable technologies and real-world healthcare data. The company aims to shift care from reactive treatment toward predictive, continuous and personalized healthcare services.
The update highlights third-party research projecting rapid growth for AI chronic disease prevention and digital chronic disease management markets over the next decade, underscoring rising demand for predictive analytics and remote monitoring solutions. Management emphasized continued investment in technology capabilities and ecosystem partnerships to support its long-term vision for predictive healthcare infrastructure.
POMDOCTOR LIMITED, a China-based digital healthcare company, has announced a strategic upgrade, repositioning itself as a foundational infrastructure provider for predictive healthcare data and services rather than a traditional online consultation platform.
The company plans to integrate wearable devices, artificial intelligence, physician resources, real-world healthcare data and healthcare payment networks into a single intelligent ecosystem. This platform is intended to support continuous monitoring, early risk identification, diagnosis, treatment, rehabilitation and long-term chronic disease management with diversified revenue streams beyond pharmaceutical sales.
POMDOCTOR describes a healthcare intelligence “flywheel” in which wearable data feed an analysis and prediction engine, inform physician intervention, and connect with insurers to support value-based care. Management highlights chronic disease trends, advances in AI and remote monitoring, and shifting reimbursement models as key drivers, and notes ambitions to expand internationally, with the United States as an important next step.
POMDOCTOR LIMITED is implementing an ADS ratio change that will take effect on June 22, 2026, U.S. Eastern Time. Each American depositary share will change from representing one-sixth of a Class A ordinary share to representing three Class A ordinary shares.
For ADS holders, this functions as a one-for-eighteen reverse ADS split: every eighteen existing ADSs will be automatically exchanged for one new ADS, with no action required by holders. No changes are being made to the underlying Class A ordinary shares.
POMDOCTOR’s ADSs are expected to begin trading on Nasdaq on a post-reverse ADS split basis under the same ticker “POM” on the effective date. The company states that the ADS trading price is expected to increase proportionally, but it gives no assurance that the post-change price will equal or exceed eighteen times the prior price.
POMDOCTOR LIMITED plans a major change to its American Depositary Share structure. Each ADS will shift from representing one-sixth of a Class A ordinary share to representing three Class A ordinary shares, effectively a one-for-eighteen reverse ADS split for ADS holders.
The company expects the ADS ratio change to take effect on or about June 22, 2026, after a post-effective amendment to its Form F-6 becomes effective. Existing ADSs held through DRS and DTC will be automatically exchanged, with eighteen current ADSs consolidated into one new ADS.
Fractional new ADS entitlements will be aggregated and sold by Citibank, N.A., the depositary bank, with net cash proceeds distributed to ADS holders. The company states that the change will not affect the underlying Class A ordinary shares, which will not be issued or cancelled, and the ADSs will continue trading on Nasdaq under the ticker “POM.”
Pomdoctor Limited reported strong top-line growth but sharply higher losses for fiscal 2025. Net revenues rose 16.7% to RMB399.9 million (US$57.2 million), driven mainly by expansion of its Internet hospital business and online pharmacy sales. Gross profit increased 9.6% to RMB52.3 million (US$7.5 million), with gross margin dipping slightly to 13.1% from 13.9%.
Operating expenses more than doubled to RMB170.9 million (US$24.4 million) as the company boosted R&D by 328.5% and incurred significant non-recurring IPO-related costs. Net loss widened to RMB130.9 million (US$18.7 million) from RMB37.4 million, and net cash used in operating activities jumped to RMB148.5 million (US$21.2 million). Pomdoctor completed a Nasdaq IPO in October 2025, raising gross proceeds of US$23.0 million, which helped lift cash and cash equivalents to RMB9.6 million (US$1.4 million) at year-end.
PomDoctor Limited filed its 2025 Form 20-F reporting rapid revenue growth but deepening losses and going-concern risk. Net revenues reached RMB399.9 million for 2025, up from RMB342.6 million in 2024 and RMB304.9 million in 2023, driven by its China-based digital healthcare platform.
The company recorded a 2025 net loss of RMB130.9 million (US$18.7 million) and negative operating cash flow of RMB148.5 million, with net current liabilities of RMB113.2 million as of December 31, 2025. Its auditor expressed substantial doubt about PomDoctor’s ability to continue as a going concern.
PomDoctor operates as a Cayman holding company relying on a variable interest entity structure in China, exposing investors to PRC regulatory, foreign exchange, data security and HFCAA-related risks that could affect its ADS listing and the value of its securities.
POMDOCTOR Ltd disclosed an initial ownership report for director Bao Wenqing. The filing identifies Bao as a director of the company but shows no reported stock transactions or derivative positions, and the transaction summary indicates zero buys, sells, exercises, gifts, or other movements.